Type 2 Diabetes Clinical Trial
Official title:
Effect of Metformin Glycinate on Postprandial Lipemia, Glycemic Control and Oxidation Markers in Type 2 Diabetes Patients
The aim of this study is to evaluate the effect of metformin glycinate vs metformin
hydrochloride on postprandial lipemia. 72 patients will be included, they will be randomized
and assigned into one of the two treatment groups: metformin glycinate 1240 mg BID or
metformin hydrochloride 1000 mg BID (36 patients per group). The patients will be followed
for 4 months.
Blood count, blood chemistry, liver profile, lipid profile, HbA1c, apolipoprotein B, oxidized
LDL, fibroblast growth factor 21, leptin, adiponectin, C-reactive protein, free fatty acids,
fibrinogen, Goodpasture Binding Protein (GPBP) and antioxidant activity of plasma will be
measured at baseline and 4 months.
Additionally, after a structured meal, the following parameters will be measured: glucose,
insulin, triglycerides, apolipoprotein B and oxidized LDL. (baseline and 4 months).
Throughout the study adverse events will be documented.
Main objective: To compare the effect of metformin glycinate with metformin hydrochloride
postprandial lipemia (area under the curve of triglycerides)
Study group
Tablets of 620 mg of metformin glycinate. Scaling: 1 tablet at night for 3 days, followed by
1 tablet in the morning and 1 tablet at night for 3 days, followed by 1 tablet in the morning
and 2 tablets in the evening for 3 days and finally, 2 tablets in the morning and 2 tablets
in the evening to complete the study. Final study dose 1240 mg every 12 hours.
Comparative group
500 mg tablets of metformin hydrochloride. Scaling: 1 tablet at night for 3 days, followed by
1 tablet in the morning and 1 tablet at night for 3 days, followed by 1 tablet in the morning
and 2 tablets in the evening for 3 days and finally, 2 tablets in the morning and 2 tablets
in the evening to complete the study. Final study dose 1000 mg every 12 hours.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05219994 -
Targeting the Carotid Bodies to Reduce Disease Risk Along the Diabetes Continuum
|
N/A | |
| Completed |
NCT04056208 -
Pistachios Blood Sugar Control, Heart and Gut Health
|
Phase 2 | |
| Completed |
NCT02284893 -
Study to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin in Combination With Metformin Compared to Sitagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Therapy Alone
|
Phase 3 | |
| Completed |
NCT04274660 -
Evaluation of Diabetes and WELLbeing Programme
|
N/A | |
| Active, not recruiting |
NCT05887817 -
Effects of Finerenone on Vascular Stiffness and Cardiorenal Biomarkers in T2D and CKD (FIVE-STAR)
|
Phase 4 | |
| Active, not recruiting |
NCT05566847 -
Overcoming Therapeutic Inertia Among Adults Recently Diagnosed With Type 2 Diabetes
|
N/A | |
| Recruiting |
NCT06007404 -
Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
|
||
| Completed |
NCT04965506 -
A Study of IBI362 in Chinese Patients With Type 2 Diabetes
|
Phase 2 | |
| Recruiting |
NCT06115265 -
Ketogenic Diet and Diabetes Demonstration Project
|
N/A | |
| Active, not recruiting |
NCT03982381 -
SGLT2 Inhibitor or Metformin as Standard Treatment of Early Stage Type 2 Diabetes
|
Phase 4 | |
| Completed |
NCT04971317 -
The Influence of Simple, Low-Cost Chemistry Intervention Videos: A Randomized Trial of Children's Preferences for Sugar-Sweetened Beverages
|
N/A | |
| Completed |
NCT04496154 -
Omega-3 to Reduce Diabetes Risk in Subjects With High Number of Particles That Carry "Bad Cholesterol" in the Blood
|
N/A | |
| Completed |
NCT04023539 -
Effect of Cinnamomum Zeylanicum on Glycemic Levels of Adult Patients With Type 2 Diabetes
|
N/A | |
| Recruiting |
NCT05572814 -
Transform: Teaching, Technology, and Teams
|
N/A | |
| Enrolling by invitation |
NCT05530356 -
Renal Hemodynamics, Energetics and Insulin Resistance: A Follow-up Study
|
||
| Completed |
NCT04097600 -
A Research Study Comparing Active Drug in the Blood in Healthy Participants Following Dosing of the Current and a New Formulation (D) Semaglutide Tablets
|
Phase 1 | |
| Completed |
NCT03960424 -
Diabetes Management Program for Hispanic/Latino
|
N/A | |
| Completed |
NCT05378282 -
Identification of Diabetic Nephropathy Biomarkers Through Transcriptomics
|
||
| Active, not recruiting |
NCT06010004 -
A Long-term Safety Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes
|
Phase 3 | |
| Completed |
NCT03653091 -
Safety & Effectiveness of Duodenal Mucosal Resurfacing (DMR) Using the Revita™ System in Treatment of Type 2 Diabetes
|
N/A |